8-K: Serina Therapeutics Secures $5 Million to Advance Parkinson's Drug

Serina Therapeutics has secured $5 million in funding to support the clinical development of SER-252 for advanced Parkinson's disease.

Summary

• Serina Therapeutics, Inc. has entered into a Securities Purchase Agreement with investors for a private placement, raising approximately $5 million.
• The company will issue 962,250 shares of Series A Convertible Preferred Stock at $5.18 per share.
• Each share of Series A Preferred Stock is convertible into common stock at a price of $5.18 per share.
• The Series A Preferred Stock carries an annual 8.0% cumulative dividend, payable in kind on March 31st of each year, beginning in 2026.
• Holders of Series A Preferred Stock have voting rights equal to the number of common shares into which their preferred stock can be converted.
• All shares of Series A Preferred Stock will automatically convert into common stock if the common stock price is greater than two times the conversion price for ten trading days within any twenty consecutive trading days, or upon completing an underwritten offering or private placement of Common Stock resulting in gross cash proceeds to the Company of at least $20 million.
• The company plans to file a registration statement with the SEC to register the resale of the conversion shares and PIK shares.
• Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.

Sentiment

Score: 8

Explanation: The announcement is positive due to the successful financing and the advancement of a key drug candidate into clinical development. The company has secured funding to progress its lead asset, which is a positive signal for investors.

Positives

• The $5 million financing strengthens Serina Therapeutics' cash position.
• The funding will support the advancement of SER-252 into clinical development.
• Strategic investors have shown confidence in the potential of SER-252.
• The company is preparing to initiate a Phase 1 clinical trial for SER-252 in Q4 2025.
• SER-252 offers a novel approach to continuous dopaminergic stimulation for Parkinson's patients.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those inherent in research and development.
• Clinical trial data may be subject to differing interpretations by regulatory authorities.
• Regulatory authorities may not be satisfied with the design and results of clinical studies.
• There is a risk of unfavorable new clinical data and further analyses of existing clinical data.
• The company may face competitive developments in the market.

Future Outlook

Serina Therapeutics plans to use the proceeds to advance SER-252 into clinical development, with a Phase 1 trial expected to begin in the fourth quarter of 2025. The company believes SER-252 may offer meaningful clinical benefit to patients with advanced Parkinson's disease.

Management Comments

• Steve Ledger, CEO of Serina Therapeutics, stated that the financing strengthens the company's cash position and reflects confidence in SER-252.
• He believes SER-252 may offer meaningful clinical benefit to patients with advanced Parkinson's disease.

Industry Context

The announcement highlights the ongoing efforts to develop new treatments for Parkinson's disease, particularly advanced stages where motor complications are prevalent. Serina's approach focuses on continuous dopaminergic stimulation, a strategy aimed at reducing these complications and improving patient outcomes.

Comparison to Industry Standards

• Other companies developing treatments for Parkinson's disease include AbbVie (Duopa), Neurocrine Biosciences (Ongentys), and Acorda Therapeutics (Inbrija).
• Serina's SER-252 aims to provide continuous dopaminergic stimulation (CDS), similar to AbbVie's Duopa, but with a potentially more convenient subcutaneous injection via Enable Injections' enFuse wearable drug delivery platform.
• The POZ platform delivery technology is designed to improve the pharmacokinetic profiles of existing drugs, potentially offering advantages over traditional formulations.

Stakeholder Impact

• Shareholders will benefit from the company's strengthened financial position and the potential for SER-252 to generate value.
• Patients with advanced Parkinson's disease may benefit from a new treatment option that provides continuous dopaminergic stimulation.
• Employees will have the opportunity to work on a promising clinical program.
• Strategic investors have demonstrated their confidence in the company's technology and prospects.

Next Steps

• Serina Therapeutics will file a registration statement with the SEC to register the resale of the conversion shares and PIK shares.
• The company will prepare to initiate a Phase 1 clinical trial for SER-252 in the fourth quarter of 2025.

Key Dates

Keywords

Serina Therapeutics, Private Placement, Series A Preferred Stock, SER-252, Parkinson's Disease, Clinical Trial, Financing, POZ Platform, Convertible Stock, Apomorphine